Curaleaf Responds to Aurora Circular; Reaffirms Offer as the Best Path to Value Creation for Shareholders
Curaleaf Responds to Aurora Circular; Reaffirms Offer as the Best Path to Value Creation for Shareholders PR Newswire
ACB - Aurora Cannabis Inc.
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$5.92
DETAILS
HIGH:
$8.75
LOW:
$1.00
MEDIAN:
$8.00
CONSENSUS:
$5.92
UPSIDE:
49.87%
Stock News
Aurora Cannabis Calls Curaleaf Offer Inadequate, Urges Rejection
Aurora Cannabis is urging its shareholders to reject an unsolicited $272 million hostile takeover bid from Curaleaf Holdings.
Aurora Cannabis Urges Shareholders to REJECT Curaleaf's Hostile Bid, Warning that it is Inadequate, Undervalues Aurora and Puts Shareholder Value and Future Upside at Risk
NASDAQ | TSX: ACB Curaleaf's hostile and opportunistic bid significantly undervalues Aurora, and aims to capture Aurora's assets at a discount Aurora is debt free and holds $149 million in cash 1 , Curaleaf carries over $1 billion in debt 2 , Aurora shareholders' own cash should not be used to help fix Curaleaf's balance sheet The hostile bid exposes Aurora shareholders to significant risks not fairly disclosed and could meaningfully weaken shareholder rights Aurora's transformation into a global, high-margin medical cannabis leader is delivering results, and the Board believes significant value creation lies ahead Aurora Files Directors' Circular Unanimously Recommending Shareholders REJECT Curaleaf's Hostile Bid by TAKING NO ACTION and NOT TENDERING their shares To keep current with and obtain information about the hostile bid, please visit www.ProtectAurora.com EDMONTON, AB, Sept. 2, 2026 /PRNewswire/ -- Aurora Cannabis Inc. ("Aurora" or the "Company") (TSX: ACB) (NASDAQ: ACB), the leading Canadian-based global medical cannabis company, today urged shareholders to reject the unsolicited take-over bid ("Hostile Bid") from Curaleaf Holdings, Inc. ("Curaleaf") (TSX: CURA) (OTCQX: CURLF), warning that the Hostile Bid would put Aurora shareholders' value and future upside at risk.
Is Aurora Cannabis Stock a Buy as Curaleaf Pushes a Hostile Takeover Bid?
Curaleaf is offering Aurora shareholders $4 per share. Aurora believes Curaleaf's hostile bid undervalues the company.
Curaleaf Responds to Aurora Cannabis' Latest Attempt to Deflect From Shareholder Value Creation
Aurora's selective statistics and misleading characterization of engagement do not obscure years of underperformance and lost shareholder value Curaleaf reiterates its willingness to meet anytime to discuss a deal in the best interests of shareholders STAMFORD, Conn., Aug. 24, 2026 /PRNewswire/ -- Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) ("Curaleaf"), a leading international provider of consumer and medical cannabis products, today responded to Aurora Cannabis Inc.'s (TSX: ACB) (NASDAQ: ACB) ("Aurora") latest public statements regarding Curaleaf's offer for Aurora: "Aurora's hollow protests and completely misleading statistics change nothing about reality: if its multi-year turnaround strategy were delivering the value management claims, the company's valuation would reflect it.
AURORA CANNABIS CORRECTS INACCURATE STATEMENTS MADE IN SUPPORT OF CURALEAF HOLDINGS' HOSTILE BID
Curaleaf's self-serving portrayal of our business is an attempt to acquire Aurora's world class EU-GMP manufacturing facilities and global medical cannabis footprint at the lowest price possible Aurora's international strategy is working; net revenue is up 17%YOY Contrary to Curaleaf's inaccurate statements, Aurora's high margin German business is growing and continues to be a key driver of Aurora's international growth strategy Shareholders are advised to TAKE NO ACTION pending formal recommendation from the Board and Special Committee. Offer remains open for at least 105 days from the launch of the Hostile Bid Questions about the Offer or would like to stay informed?
The Cannabis M&A Wave Is Here. Curaleaf Proved It.
Green Thumb Industries is one of the few U.S. cannabis companies that has been consistently profitable. The company grew revenue and earnings in the second quarter.
Curaleaf's Hostile Takeover Bid for Aurora Is Just the Tip of the Iceberg for Cannabis Consolidation. These 2 Stocks Could Be the Biggest Winners.
Curaleaf has made an unsolicited bid for Aurora Cannabis. Aurora recently completed its acquisition of Safari Flower.
Is Curaleaf Stock a Buy With Its Attempted Hostile Takeover of Aurora Cannabis Under Way?
Curaleaf reiterated the offer it made public last week. Aurora stock continues to trade at a discount to the base offer price.
Tilray Jumps 6%, Canopy Growth Climbs 3%, Aurora Cannabis Gains 4%: Here's Why TLRY Is Still Down 47% YTD
Shares of Tilray Brands (NASDAQ:TLRY) are up 6% to $4.75 Wednesday afternoon, participating in a broad bid for beaten-down speculative names.
Aurora Cannabis Furthers Global Medical Cannabis Growth with Accretive Acquisition of Internode Pharma Limited and HAP Pharma Limited, Expanding Distribution Access to the UK Medical Cannabis Market
Aurora Cannabis Furthers Global Medical Cannabis Growth with Accretive Acquisition of Internode Pharma Limited and HAP Pharma Limited, Expanding
Aurora Cannabis Furthers Global Medical Cannabis Growth with Accretive Acquisition of Internode Pharma Limited and HAP Pharma Limited, Expanding Distribution Access to the UK Medical Cannabis Market
EDMONTON, AB, Aug. 19, 2026 /PRNewswire/ -- Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, is pleased to announce that it has acquired Internode Pharma Limited, a licensed importer and wholesaler, and HAP Pharma Limited, a licensed pharmacy (the "Companies"). "The acquisition of Internode Pharma Limited and HAP Pharma Limited mark a further strategic milestone for Aurora as we continue to purposefully invest in expanding our leadership in the rapidly growing international medical cannabis market.
AURORA CANNABIS INC. URGES SHAREHOLDERS TO TAKE NO ACTION AT THIS TIME IN RESPECT TO THE UNSOLICITED TAKE-OVER BID BY CURALEAF HOLDINGS, INC.
Curaleaf's decision to launch a hostile takeover bid is designed to pressure Aurora's shareholders into a short-term decision for the benefit of Curaleaf shareholders. Curaleaf's actions and comments reflect its objective: to acquire, at the lowest price possible, Aurora's market-leading EU-GMP facilities and global medical cannabis platform.
Curaleaf CEO talks unsolicited offer to buy Aurora Cannabis
Curaleaf Chairman and CEO Boris Jordan joins 'Fast Money' to talk the cannabis company's bid for Aurora Cannabis.
Curaleaf Wants to Buy Aurora Cannabis for $272 Million. Is Canopy Growth the Next Marijuana Takeover Target?
Curaleaf's bid signals cannabis consolidation is accelerating. Canopy Growth could emerge as another takeover candidate.
Marijuana reform is emerging as a midterm elections issue on both sides of the aisle
With November's pivotal midterm elections fast approaching, cannabis reform is emerging as an issue. Two states, Massachusetts and Idaho, will vote on ballot initiatives regarding legalization, and in several others, including Kansas and Iowa, gubernatorial candidates are debating cannabis matters.
Is Acquiring Aurora Cannabis a Good Move for Curaleaf?
Curaleaf has announced a hostile bid for Aurora Cannabis. Aurora has a strong international presence, but it's had challenges with staying out of the red.
Should You Buy ACB Stock Amid Curaleaf's Hostile Takeover Attempt?
Aurora Cannabis faces a potential Curaleaf takeover at a 45% premium, but investors must weigh the offer against ACB's standalone prospects.
Curaleaf Just Announced a Hostile Takeover Bid for Aurora Cannabis. Here's What This Means for Investors.
Aurora criticized key aspects of the bid, but will consider it. The major appeal of Aurora is its strong medical marijuana business.
AURORA CANNABIS INC. RESPONDS TO PRESS RELEASE OF CURALEAF HOLDINGS, INC. REGARDING INTENTION TO LAUNCH UNSOLICITED TAKE-OVER BID
AURORA CANNABIS INC. RESPONDS TO PRESS RELEASE OF CURALEAF HOLDINGS, INC. REGARDING INTENTION TO LAUNCH UNSOLICITED TAKE-OVER BID
Price Targets
Aurora Cannabis Stock Receives A $1 Price Target (ACB)
$1.00
(was $0.88)
EBITDA Q3
·
Piper Sandler
BofA Securities Reiterates Neutral Rating on Aurora Cannabis Inc. (ACB:CN) (ACB)
$11.00
(was $9.66)
Heather Balsky
·
Bank of America Securities
Aurora Cannabis upgraded to Market Perform from Underperform at BMO Capital
$8.00
(was $6.86)
Tamy Chen
·
BMO Capital